8-K
filed January 25, 2023, 6:59 PM ET
ticker CVKD
CIK 0001937993
other material
confidence high
sentiment positive
materiality 0.90
Cadrenal Therapeutics completes $7M IPO at $5/share and receives FDA Fast Track for tecarfarin
Cadrenal Therapeutics, Inc.
- IPO of 1.4M shares at $5.00 closed Jan 24, raising $7.0M gross; stock trades on Nasdaq as CVKD.
- FDA granted Fast Track designation for tecarfarin in ESRD and atrial fibrillation patients.
- Appointed directors: Glynn Wilson (Class I), John Murphy (Class II), Steven Zelenkofske (Class III).
- Employment agreements: CFO Szot ($375K salary, 50% target bonus); CMO Losordo ($425K, 40% bonus).
- Issued 600K shares to HESP LLC, 1.14M on note conversion, 250K on warrant exercise.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.9
Douglas Losordo was appointed as Chief Medical Officer at Cadrenal Therapeutics, Inc..
- Action
- appointed
- Role
- Chief Medical Officer
Exact text from the filing
Upon completion of the IPO, we entered into an employment agreement with each of Matthew Szot, the Company’s Chief Financial Officer, and Douglas Losordo, the Company’s Chief Medical Officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Steven Zelenkofske was appointed as Class III Director at Cadrenal Therapeutics, Inc..
- Action
- appointed
- Role
- Class III Director
Exact text from the filing
Steven Zelenkofske was appointed as a Class III director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
John Murphy was appointed as Class II Director at Cadrenal Therapeutics, Inc..
- Action
- appointed
- Role
- Class II Director
Exact text from the filing
John Murphy was appointed as a Class II director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.9
Matthew Szot was appointed as Chief Financial Officer at Cadrenal Therapeutics, Inc..
- Action
- appointed
- Role
- Chief Financial Officer
Exact text from the filing
Upon completion of the IPO, we entered into an employment agreement with each of Matthew Szot, the Company’s Chief Financial Officer, and Douglas Losordo, the Company’s Chief Medical Officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Glynn Wilson was appointed as Class I Director at Cadrenal Therapeutics, Inc..
- Action
- appointed
- Role
- Class I Director
Exact text from the filing
Glynn Wilson was appointed as a Class I director
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Cadrenal Therapeutics, Inc. entered into Underwriting Agreement with Boustead Securities, LLC (as representative of the underwriters) valued at Gross proceeds of $7,000,000 from sale of 1,400,000 shares at $5.00 per share; Representative's Warr (effective 2023-01-19).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Boustead Securities, LLC (as representative of the underwriters)
- Value
- Gross proceeds of $7,000,000 from sale of 1,400,000 shares at $5.00 per share; Representative's Warr
- Effective
- 2023-01-19
Exact text from the filing
On January 19, 2023, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Boustead Securities, LLC, as representative of the underwriters (the “Representative”), a form of which was previously filed as an exhibit to the Company’s registration statement on Form S-1, as amended (File No. 333-267562), which was declared effective by the Securities and Exchange Commission (the “Commission”) on January 19, 2023 (the “Registration Statement”).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.